Navigation Links
PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
Date:9/1/2010

a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:--  The expected rate of growth in royalty-bearing product sales by PDL's
existing licensees;
--  The relative mix of royalty-bearing Genentech products manufactured and sold
outside the U.S. versus manufactured or sold in the U.S.;
--  The ability of our licensees to receive regulatory approvals to market
and launch new royalty-bearing products and whether such products, if
launched, will be commercially successful;
--  Changes in any of the other assumptions on which PDL's projected royalty
revenues are based;
--  The outcome of pending litigation or disputes; and
--  The failure of licensees to comply with existing license agreements,
including any failure to pay royalties due.Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be ob
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reportlinker Adds Advances in Biopharmaceutical Technology in China
2. PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock
3. Therapure Biopharma Inc. Signs Biomanufacturing Contract with Diamedica Incorporated
4. Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life
5. Progenika Biopharma Grants Grifols World-Wide Distribution Rights for the BLOODCHIP® Genotyping Test for Blood Donors
6. Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd.
7. Chinese Biopharmaceutical Association Holds 15th Annual Conference in Rockville, MD, June 12 - 13
8. IntraLinks Announces Partnership With SAFE-BioPharma; Will Provide Digital Identity Capabilities With its Life Sciences Solutions
9. PDL BioPharma to Announce First Quarter 2010 Financial Results and Hold Conference Call on April 29, 2010
10. PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
11. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... British Columbia , March 2, 2015 ... IMLFF), a clinical stage biopharmaceutical company specializing in ... that Craig Schneider , Chief Executive Officer, ... webcast at VirtualInvestorConferences.com. DATE: Thursday, March ... > click the red "register/ watch event now" ...
(Date:3/2/2015)... -- Editor Note: For more information about ... Moments ago, Analysts Review released new research updates concerning several ... SSH ), Synergetics USA (NASDAQ: ... ), Spectranetics (NASDAQ: SPNC ), and Thoratec (NASDAQ: ... platform for investors, to hear about what matters - proudly ...
(Date:3/2/2015)... Kent, WA (PRWEB) March 02, 2015 ... tangential flow flat-sheet testing system at the 2015 AMTA ... is a culmination of a decade’s worth of engineering ... system compatible with a wide range of applications across ... be versatile enough to meet the dynamic needs of ...
(Date:3/1/2015)... 2015 Market Publishers Ltd and ... market research promotion on Internet. MarketPublishers.com is now ... out by DataGroup Booksellers. , Natalie Aster, Assistant ... commented on the recent partnership agreement as follows: ... our team of publishers. Since 1974, the company ...
Breaking Biology Technology:InMed Pharmaceuticals to Present Investor Webcast March 5 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4Sterlitech Displays Complete CF042 Membrane Test System 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3
... to data may provide potential for label expansion in ... Inc.,(CTI) (Nasdaq: CTIC ; MTA) announced today an ... phase III Zevalin(R) ([90Y]-ibritumomab,tiuxetan) First-line Indolent Trial, FIT data. ... appropriate for CTI to begin discussions with the,U.S. Food ...
... June 17 MEDRAD, INC., announced today,that ... new Fluorodeoxyglucose (FDG),Infusion System for Positron Emission ... PET Infusion System is the,first infusion system ... the FDG,delivery process., (Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO ...
... has published a,new report designed to provide critical ... stake in the market for diagnostics and treatments,in ... Insight &,Analysis: Alzheimer,s Disease," is based on in-depth ... actively involved in ongoing,research., "There is some ...
Cached Biology Technology:CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 2CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 3CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 5CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 6MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 3Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimer's Disease in MedPredict Report 2
(Date:2/5/2015)... Feb. 3, 2015 Despite a lack ... industries such as consumer electronics, automotive, storage and ... mount technology (SMT) screen printers. Innovations in electronics ... will push the adoption curve up. Meanwhile, sale ... as glue dispensers are indispensable in the production ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... anaplastic lymphoma kinase, which has been reported in other ... a primary driver of the rapid metastasis that patients ... the use of anaplastic lymphoma kinase (ALK) inhibitors may ... lethal form of breast cancer. These data were ...
... scientist who is leading a multinational effort to improve ... an award for his work from the central Asian ... Academy of Natural Sciences of Drexel University, recently received ... his "significant contribution in Mongolian Environmental Science." The award ...
... press release is available in German . ... myriad smells in the air with the aid of odorant ... gene for expression. The probability that a particular receptor gene ... in total produce this receptor type. Scientists from the Max ...
Cached Biology News:Signaling pathway linked to inflammatory breast cancer may drive disease metastasis 2Gene switch for odorant receptors 2Gene switch for odorant receptors 3
Polymerase (RNA) II (DNA directed) polypeptide L...
... PI is used in conjuction with Annexin ... the earlier stages of apoptosis (Annexin V ... in later stages of apoptosis or already ... is detected in the orange range of ...
BD Primaria 35 mm Cell Culture Dish with Easy-Grip design, surface-modified polystyrene for enhanced cell culture. (20/sp, 200/ca) Packaging: 20 / sleeve, 500 / case ...
... DNA Polymerase is a premium quality recombinant ... thermostable enzyme is suitable for a wide ... highest purity and reproducible performance, each preparation ... quality control assays. NovaTaq DNA Polymerase possesses ...
Biology Products: